Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy

Kidney International

Volumn 79, Issue 10, 2011, Pages 1113-1118

  Nielsen, Stine E ^a   Andersen, Steen ^a   Zdunek, Dietmar ^b   Hess, Georg ^c   Parving, Hans Henrik ^d,e   Rossing, Peter ^a  

^a STENO DIABETES CENTER   (Denmark)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d Rigshospitalet   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

diabetes mellitus; diabetic nephropathy; tubule cells

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; KIDNEY INJURY MOLECULE 1; LIVER FATTY ACID BINDING PROTEIN; LOSARTAN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; UNCLASSIFIED DRUG;

ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ACTIVITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT DURATION; URINARY EXCRETION; URINE LEVEL;

EID: 79955612433     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.554     Document Type: Article

References (22)

1. Finne P, Reunanen A, Stenman S et al. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005; 294: 1782-1787. (Pubitemid 41434624)
2. Parving H-H, Jacobsen P, Rossing K et al. Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int 1996; 49: 1778-1782. (Pubitemid 26186611)
3. Gaede P, Lund-Andersen H, Parving H-H et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591. (Pubitemid 351214285)
4. Parving H-H, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM (ed). Brenner & Rector's THE KIDNEY, 8th edn. WB Saunders: Boston, USA, 2008, pp 1265-1298.
5. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury? Kidney Int 1999; 56: 1627-1637. (Pubitemid 29518163)
6. Cowland JB, Sorensen OE, Sehested M et al. Neutrophil gelatinase associated lipocalin is up-regulated in human epithelial cells by IL-1 β, but not by TNF-α. J Immunol 2003; 171: 6630-6639. (Pubitemid 37532095)
7. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int 2007; 71: 967-970. (Pubitemid 46741985)
8. Kamijo A, Sugaya T, Hikawa A et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004; 165: 1243-1255. (Pubitemid 39297730)
9. van Timmeren MM, van den Heuvel MC, Bailly V et al. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 2007; 212: 209-217. (Pubitemid 46852099)
10. Nielsen SE, Schjoedt KJ, Astrup AS et al. Neutrophil gelatinase- associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med 2010; 27: 1144-1150.
11. Nielsen SE, Sugaya T, Hovind P et al. Urinary liver-type fatty acid-binding protein (u-LFABP) predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 2010; 33: 1320-1324.
12. Nielsen SE, Sugaya T, Tarnow L et al. Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care 2009; 32: 1684-1688.
13. Andersen S, Tarnow L, Cambien F et al. Long-Term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/ deletion genotype? Diabetes Care 2003; 26: 1501-1506. (Pubitemid 36929186)
14. Schjoedt KJ, Andersen S, Rossing P et al. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47: 1936-1939. (Pubitemid 40110201)
15. Kelly DJ, Cox AJ, Tolcos M et al. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int 2002; 61: 31-39. (Pubitemid 34075128)
16. Bader R, Bader H, Grund KE et al. Structure and function of the kidney in diabetic glomerulosclerosis: correlations between morphological and functional parameters. Pathol Res Pract 1980; 167: 204-216. (Pubitemid 10081929)
17. Bolignano D, Lacquaniti A, Coppolino G et al. Neutrophil gelatinase associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 337-344.
18. Bolignano D, Donato V, Coppolino G et al. Neutrophil gelatinase associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008; 52: 595-605.
19. Vaidya VS, Ramirez V, Ichimura T et al. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006; 290: F517-F529. (Pubitemid 43725006)
20. Waanders F, Vaidya VS, van GH et al. Effect of renin- angiotensinaldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Am J Kidney Dis 2009; 53: 16-25.
21. Wagener G, Lee HT. In Reply to [']instability of urinary NGAL during longterm storage' and [']NGAL and cardiac surgery-associated acute kidney injury'. Am J Kidney Dis 2009; 53: 566.
22. Bröchner-Mortensen J, Rödbro P. Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 1976; 36: 35-45.